Ann: Incannex to Acquire APIRx Pharmaceuticals, page-100

This is reminiscent of Google buying Motorola about 10 years ago and people not understanding that it was done to acquire their IP patents, technology and research. After spinning off asests and cash on hand only cost Google
3.5 billion for patent portfolio.

Here we have just secured the rights to aquire a boat load of patents, technology, key staff and opinion leaders along with $40 million of prior research all for $93 million in future shares, so ~12-15% dilution pending the 7 day VWAP.

Interestingly IHL had already partnered with AXIM for the Periodontitis Trial back in 2019, but this partnership was dissolved.
Below is exerpt from the NASDAQ filing.

Income from other arrangements for the fiscal year ended 30 June 2020 was a result of a transaction entered into with AXIM Biotechnologies, in consideration of the terms of the full understanding 6,800,000 IHL shares were issued in full consideration of the intended transaction.

AXIM was not able to fulfil their part of the transaction, and the contract was terminated. In lieu of returning the shares, the Company received cash.

This will take some time for the market (read as retail) punters to understand hence the lower trade volume, but I for one am constantly blown away by the strategic moves that are continuing to be played out by the BOD and management.